Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients

Detalles Bibliográficos
Autores principales: Aqeel, Faten, Geetha, Duvuru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419428/
https://www.ncbi.nlm.nih.gov/pubmed/36060620
http://dx.doi.org/10.1016/j.ekir.2022.08.019
_version_ 1784777173127659520
author Aqeel, Faten
Geetha, Duvuru
author_facet Aqeel, Faten
Geetha, Duvuru
author_sort Aqeel, Faten
collection PubMed
description
format Online
Article
Text
id pubmed-9419428
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94194282022-08-30 Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients Aqeel, Faten Geetha, Duvuru Kidney Int Rep Letter to the Editor Elsevier 2022-08-27 /pmc/articles/PMC9419428/ /pubmed/36060620 http://dx.doi.org/10.1016/j.ekir.2022.08.019 Text en © 2022 International Society of Nephrology. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Letter to the Editor
Aqeel, Faten
Geetha, Duvuru
Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
title Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
title_full Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
title_fullStr Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
title_full_unstemmed Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
title_short Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
title_sort tixagevimab and cilgavimab (evusheld) in rituximab-treated antineutrophil cytoplasmic antibody vasculitis patients
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419428/
https://www.ncbi.nlm.nih.gov/pubmed/36060620
http://dx.doi.org/10.1016/j.ekir.2022.08.019
work_keys_str_mv AT aqeelfaten tixagevimabandcilgavimabevusheldinrituximabtreatedantineutrophilcytoplasmicantibodyvasculitispatients
AT geethaduvuru tixagevimabandcilgavimabevusheldinrituximabtreatedantineutrophilcytoplasmicantibodyvasculitispatients

Ejemplares similares